Myriad Genetics (MYGN) Assets Average (2011 - 2026)

Myriad Genetics (MYGN) has 16 years of Assets Average data on file, last reported at $690.2 million in Q1 2026.

• Assets Average for Q1 2026 came in at $690.2 million, down 32.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $690.2 million (down 32.13% YoY), and the FY2025 annual result was $867.1 million, down 20.23% from the prior year.
• Assets Average fell to $690.2 million in Q1 2026 per MYGN's latest filing, from $717.4 million in the prior quarter.
• Over five years, Assets Average peaked at $1.3 billion in Q1 2022 and troughed at $690.2 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average retreated 3.55% in 2023, then sank 35.13% in 2025.
• A 5-year view of Assets Average shows it stood at $1.2 billion in 2022, then slipped by 4.77% to $1.1 billion in 2023, then fell by 8.13% to $1.1 billion in 2024, then tumbled by 31.97% to $717.4 million in 2025, then dropped by 3.79% to $690.2 million in 2026.
• Business Quant data shows MYGN's Assets Average at $690.2 million in Q1 2026, $717.4 million in Q4 2025, and $702.7 million in Q3 2025.